Physician profile
Gregg M Lanier
NPI 1720099732
$239,492.96
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 91% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $11K · 2021: $15K · 2022: $48K · 2023: $66K · 2024: $41K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Travel and Lodging: $7,720 · Food and Beverage: $6,047 · Consulting Fee: $2,641 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,723.34 |
| Travel and Lodging | $7,719.99 |
| Food and Beverage | $6,046.52 |
| Consulting Fee | $2,640.82 |
| Education | $123.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $89,563.83 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $50,792.34 | 2022-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $44,694.45 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $28,456.39 | 2019-2025 | |
| Pfizer INC. | $24,953.11 | 2019-2025 | |
| Abbott Laboratories | $270.40 | 2019-2025 | Cardiomems, 2nd Gen Centrimag Primary Console |
| Akcea Therapeutics, INC. | $171.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $170.44 | 2019-2020 | |
| Sobi, INC | $150.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.45 | 2024 | Lifevest |
| Abiomed | $53.60 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $40.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.47 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $25.39 | 2023 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $20.45 | 2023 | Camzyos |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15.51 | 2019 | |
| Preventice Services, LLC | $14.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.